Ingeborg A. Hauser

3.3k total citations
61 papers, 2.2k citations indexed

About

Ingeborg A. Hauser is a scholar working on Epidemiology, Oncology and Transplantation. According to data from OpenAlex, Ingeborg A. Hauser has authored 61 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Epidemiology, 20 papers in Oncology and 20 papers in Transplantation. Recurrent topics in Ingeborg A. Hauser's work include Renal Transplantation Outcomes and Treatments (20 papers), Cytomegalovirus and herpesvirus research (12 papers) and Neurological Complications and Syndromes (10 papers). Ingeborg A. Hauser is often cited by papers focused on Renal Transplantation Outcomes and Treatments (20 papers), Cytomegalovirus and herpesvirus research (12 papers) and Neurological Complications and Syndromes (10 papers). Ingeborg A. Hauser collaborates with scholars based in Germany, United States and Switzerland. Ingeborg A. Hauser's co-authors include Frank Thévenod, Helmut Geiger, Stefan Gauer, Michael Koziolek, Oliver Witzke, Berthold Hocher, Jan Goßmann, Martin Nitschke, Michael Bartels and Günter Wolf and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Ingeborg A. Hauser

61 papers receiving 2.1k citations

Peers

Countries citing papers authored by Ingeborg A. Hauser

Since Specialization

Citations

This map shows the geographic impact of Ingeborg A. Hauser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingeborg A. Hauser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingeborg A. Hauser more than expected).

Fields of papers citing papers by Ingeborg A. Hauser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingeborg A. Hauser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingeborg A. Hauser. The network helps show where Ingeborg A. Hauser may publish in the future.

Co-authorship network of co-authors of Ingeborg A. Hauser

This figure shows the co-authorship network connecting the top 25 collaborators of Ingeborg A. Hauser. A scholar is included among the top collaborators of Ingeborg A. Hauser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingeborg A. Hauser. Ingeborg A. Hauser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients 2023 ·Vaccines ·(unknown), (unknown), Niko Kohmer, (unknown), Sandra Ciesek, Holger F. Rabenau, Ingeborg A. Hauser, Kirsten de Groot	1
2	Increasing but insufficient neutralizing activity against Omicron-BA.1 after a second booster dose of mRNA-1273 vaccine in chronic haemodialysis patients 2022 ·Clinical Kidney Journal ·(unknown), (unknown), Niko Kohmer, (unknown), Sandra Ciesek, Holger F. Rabenau, Ingeborg A. Hauser, Kirsten de Groot	3
3	Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial 2022 ·Leukemia ·Heiner Zimmermann, Christian Koenecke, Martin Dreyling, Christiane Pott, Ulrich Dührsen, D Hahn, Norbert Meidenbauer, Ingeborg A. Hauser, Mathias Rummel, Dominik Wolf‎, Michael Heuser, Christian Schmidt, Peter Schlattmann, Matthias Ritgen, Reiner Siebert, Ilske Oschlies, Ioannis Anagnostopoulos, Ralf Ulrich Trappe	15
4	No association of genetic variants in TLR4, TNF-α, IL10, IFN-γ, and IL37 in cytomegalovirus-positive renal allograft recipients with active CMV infection—Subanalysis of the prospective randomised VIPP study 2021 ·PLoS ONE ·(unknown), Elke Schaeffeler, Oliver Witzke, Martin Nitschke, Volker Kliem, (unknown), Eva-Maria Wagner, Matthias Schwab, Ingeborg A. Hauser	2
5	Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry 2021 ·Annals of Hematology ·Heiner Zimmermann, Mirko Nitsche, Christiane Pott, Petra Reinke, Nina Babel, Robert Michael Hermann, Ingeborg A. Hauser, D Hahn, Matthias Ritgen, (unknown), Wolfram Klapper, Ioannis Anagnostopoulos, Ralf Ulrich Trappe, (unknown)	8
6	CD4⁺ T cell lymphopenia predicts mortality from Pneumocystis pneumonia in kidney transplant patients 2020 ·Clinical Transplantation ·Tilo Freiwald, Stefan Büttner, (unknown), (unknown), Simon S. Martin, Christoph Stephan, Rainer U. Pliquett, (unknown), Gundolf Schüttfort, Volkmar Jacobi, Eva Herrmann, Helmut Geiger, Ingeborg A. Hauser	16
7	Influence of the recipient body mass index on the outcomes after kidney transplantation 2017 ·Langenbeck s Archives of Surgery ·Juliane Liese, (unknown), Stefan Büttner, Alexander Reinisch, Guido Woeste, Markus Wortmann, Ingeborg A. Hauser, Wolf O. Bechstein, Frank Ulrich	20
8	Aortic Valve Stenosis in a Dialysis Patient Waitlisted for Kidney Transplantation 2016 ·The Annals of Thoracic Surgery ·Stefan Büttner, (unknown), (unknown), Benjamin Koch, Andreas Zierer, Andreas M. Zeiher, Helmut Geiger, Mariuca Vasa‐Nicotera, Ingeborg A. Hauser, Stephan Fichtlscherer	9
9	Pparγ Expression in T Cells as a Prognostic Marker of Sepsis 2016 ·Shock ·(unknown), (unknown), (unknown), (unknown), Holger Neb, Patrick Meybohm, Kai Zacharowski, Ingeborg A. Hauser, Stefan Büttner, Michael J. Parnham, Bernhard Brüne, Andreas von Knethen	5
10	Design and rationale of the ATHENA study – A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial 2016 ·Trials ·Claudia Sommerer, Barbara Suwelack, Duska Dragun, Peter Schenker, Ingeborg A. Hauser, Björn Nashan, Friedrich Thaiss	10
11	Development of urological cancers in renal transplant recipients: 30‐year experience at the Frankfurt Transplant Center 2010 ·Cancer Science ·Igor Tsaur, (unknown), Michael Probst, Roman A. Blaheta, Ernst‐Heinrich Scheuermann, Jan Goßmann, Heinz‐Georg Kachel, Ingeborg A. Hauser, Dietger Jonas, Nicholas Obermüller	36
12	Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution 2009 ·Clinical Transplantation ·Jan Goßmann, Ernst‐Heinrich Scheuermann, Heinz‐Georg Kachel, Helmut Geiger, Ingeborg A. Hauser	15
13	Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney 2008 ·Kidney International ·Anja Schramme, Mohamed S. Abdel‐Bakky, Paul Gutwein, Nicholas Obermüller, Patrick C. Baer, Ingeborg A. Hauser, Andreas Ludwig, Stefan Gauer, (unknown), (unknown), Peter Altevogt, Michael Koziolek, Éva Kiss, Hermann-Josef Gröne, Ritva Tikkanen, Itamar Goren, Heinfried H. Radeke, Josef Pfeilschifter	47
14	Synergistic induction of osteopontin by aldosterone and inflammatory cytokines in mesangial cells 2007 ·Journal of Cellular Biochemistry ·Stefan Gauer, Ingeborg A. Hauser, Nicholas Obermüller, (unknown), Helmut Geiger, Margarete Goppelt‐Struebe	18
15	Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis 2007 ·Transplant International ·Jan Goßmann, Ernst‐Heinrich Scheuermann, Štefan Porubský, Heinz‐Georg Kachel, Helmut Geiger, Ingeborg A. Hauser	52
16	An Increase in Myeloid-Related Protein Serum Levels Precedes Acute Renal Allograft Rejection 2001 ·Journal of the American Society of Nephrology ·Klaus Burkhardt, Martin Radespiel‐Tröger, Harald Rupprecht, Margarete Goppelt‐Struebe, R. Riess, Lutz Renders, Ingeborg A. Hauser, Ulrich Kunzendorf	31
17	CC chemokine receptor 5 and renal-transplant survival 2001 ·The Lancet ·Michael Fischereder, Bruno Luckow, Berthold Hocher, Rudolf P. Wüthrich, Uwe Rothenpieler, H. Schneeberger, Ulf Panzer, Rolf A.K. Stahl, Ingeborg A. Hauser, Klemens Budde, Hans‐H. Neumayer, Bernhard K. Krämer, W. Land, Detlef Schlöndorff	233
18	Effects of mycophenolic acid on human renal proximal and distal tubular cells in vitro 2000 ·Nephrology Dialysis Transplantation ·Patrick C. Baer, Stefan Gauer, Ingeborg A. Hauser, Jürgen E. Scherberich, Helmut Geiger	28
19	Up-regulation of Multidrug Resistance P-glycoprotein via Nuclear Factor-κB Activation Protects Kidney Proximal Tubule Cells from Cadmium- and Reactive Oxygen Species-induced Apoptosis 2000 ·Journal of Biological Chemistry ·Frank Thévenod, (unknown), (unknown), Ingeborg A. Hauser	274
20	Mycophenolate mofetil: therapeutic applications in kidney transplantation and immune-mediated renal disease 1999 ·Current Opinion in Nephrology & Hypertension ·Ingeborg A. Hauser, R. Bernd Sterzel	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact